MedTrace Logo

Low Dose Hemi-body Radiation For Recurrent Prostate Cancer

NCT03196778 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2022-08-10

No results posted yet for this study

Summary

Older studies in animals and humans have shown cancer responses to very low doses of whole-body or hemi-body radiation. To study the effects of low doses of radiation in patients with recurrent prostate cancer, investigators will enroll up to 21 patients for 10 fractions of low dose radiation, delivered over 5 weeks. Participants will be followed on study for 12 months, capturing PSA, CBC, QoL and blood samples for immunological analysis.

Conditions

Interventions

RADIATION

Low Dose Radiotherapy

Patients will receive 10 fractions of very low dose hemi-body radiation, delivered, twice per week, over five weeks

Sponsors & Collaborators

  • McMaster University

    collaborator OTHER

  • Mitacs

    collaborator INDUSTRY

  • Northern Ontario School of Medicine

    collaborator OTHER

  • Juravinski Cancer Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-25
Primary Completion
2022-07-18
Completion
2022-07-18

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03196778 on ClinicalTrials.gov